Call Us: 888-488-5750

Moving the needle on pharmacy benefit management

Recently, VativoRx and CEO Lisa Quarterman were pleased to be highlighted by Healthcare Tech Outlook as a Top Pharmacy Management Solution Provider for 2021.

You can read the full article here, but here’s a preview of what they had to say about VativoRx:

“VativoRx is in a class by itself when it comes to providing innovative PBM services and solutions, thanks to its established industry expertise. The company has been providing pharmacy benefit expertise as a service across the country for more than two decades. With Lisa Quarterman at the helm as the CEO and managing partner, VativoRx is wholly aware of its role and functioning in providing something that could potentially save someone’s life. This motivates the company to perform swiftly and effectively, ensuring no hiccups or lapses occur in their services. The company specializes in the delivery, affordability, and clinical management of prescription medications. The long- established relationships they share with healthcare organizations and third- party administrators enable the company to design and manage PBM programs comprehensively.”

Unveiling the Future: Navigating the Evolving Landscape of 340B Rebates.

The 340B Drug Pricing Program, established in 1992, has been a crucial component of the healthcare system, dedicated to assisting eligible healthcare organizations in serving vulnerable patient populations by granting them access to discounted drugs. At the heart of this program are the 340B rebates, which enable qualifying entities such as safety-net hospitals, community health centers, and other eligible providers to acquire medications at significantly reduced prices.

Read More »
Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »

Biosimilars — Similar But Not Identical

You may have never heard of biosimilar drugs and that’s probably because they are not commonly prescribed in the United States even though they have been around for over 20 years. So, what are biosimilar drugs? A biosimilar drug is no different in terms of safety and effectiveness than a biologic product, also known as a reference product, and while highly similar it is not identical.

Read More »